Log in

NASDAQ:BPMCBlueprint Medicines Stock Price, Forecast & News

$74.04
-1.28 (-1.70 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$74.00
Now: $74.04
$76.68
50-Day Range
$73.18
MA: $76.66
$80.10
52-Week Range
$43.29
Now: $74.04
$87.43
Volume317,400 shs
Average Volume722,965 shs
Market Capitalization$4.09 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.03
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies. In addition, the company is developing BLU-782, an inhibitor targeting the kinase ALK2 for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the ALK2 gene, ACVR1. The company has collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Read More
Blueprint Medicines logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.69 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BPMC
CUSIPN/A
Phone617-374-7580

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$66.51 million
Book Value$10.52 per share

Profitability

Net Income$-347,690,000.00
Net Margins-525.44%

Miscellaneous

Employees217
Market Cap$4.09 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$74.04
-1.28 (-1.70 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BPMC News and Ratings via Email

Sign-up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions

How has Blueprint Medicines' stock been impacted by Coronavirus (COVID-19)?

Blueprint Medicines' stock was trading at $52.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BPMC stock has increased by 41.2% and is now trading at $74.04.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Blueprint Medicines?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 2 hold ratings, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Blueprint Medicines
.

When is Blueprint Medicines' next earnings date?

Blueprint Medicines is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Blueprint Medicines
.

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Corp (NASDAQ:BPMC) released its quarterly earnings results on Thursday, July, 30th. The biotechnology company reported ($2.28) EPS for the quarter, missing analysts' consensus estimates of ($2.08) by $0.20. The biotechnology company earned $8.34 million during the quarter, compared to the consensus estimate of $7.56 million. Blueprint Medicines had a negative return on equity of 70.39% and a negative net margin of 525.44%.
View Blueprint Medicines' earnings history
.

What price target have analysts set for BPMC?

13 equities research analysts have issued 12-month price objectives for Blueprint Medicines' shares. Their forecasts range from $59.00 to $122.00. On average, they expect Blueprint Medicines' stock price to reach $98.50 in the next year. This suggests a possible upside of 33.0% from the stock's current price.
View analysts' price targets for Blueprint Medicines
.

Has Blueprint Medicines been receiving favorable news coverage?

Media stories about BPMC stock have been trending extremely negative on Thursday, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Blueprint Medicines earned a news impact score of -4.1 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.
View the latest news about Blueprint Medicines
.

Are investors shorting Blueprint Medicines?

Blueprint Medicines saw a decrease in short interest in April. As of April 30th, there was short interest totaling 3,170,000 shares, a decrease of 14.1% from the April 15th total of 3,690,000 shares. Based on an average trading volume of 812,900 shares, the days-to-cover ratio is currently 3.9 days.
View Blueprint Medicines' Short Interest
.

Who are some of Blueprint Medicines' key competitors?

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Pfizer (PFE), QUALCOMM (QCOM), Vertex Pharmaceuticals (VRTX), Amarin (AMRN) and Crispr Therapeutics (CRSP).

Who are Blueprint Medicines' key executives?

Blueprint Medicines' management team includes the following people:
  • Mr. Jeffrey W. Albers, CEO, Pres & Director (Age 48)
  • Mr. Alexis A. Borisy, Co-Founder & Director (Age 47)
  • Mr. Michael Landsittel, Chief Financial Officer (Age 47)
  • Ms. Kathryn Haviland, Chief Operating Officer (Age 43)
  • Dr. Christopher K. Murray, Sr. VP of Technical Operations (Age 56)

When did Blueprint Medicines IPO?

(BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Blueprint Medicines' stock symbol?

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Viking Global Investors LP (2.95%), Candriam Luxembourg S.C.A. (1.62%), TimesSquare Capital Management LLC (1.39%), Victory Capital Management Inc. (1.02%), Bank of New York Mellon Corp (0.82%) and Emerald Advisers LLC (0.73%). Company insiders that own Blueprint Medicines stock include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Debra Durso-Bumpus, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon.
View institutional ownership trends for Blueprint Medicines
.

Which major investors are selling Blueprint Medicines stock?

BPMC stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Peregrine Capital Management LLC, Hudson Bay Capital Management LP, CHI Advisors LLC, Trexquant Investment LP, Emerald Advisers LLC, GAM Holding AG, and Algert Global LLC. Company insiders that have sold Blueprint Medicines company stock in the last year include Anthony L Boral, Ariel Hurley, Debra Durso-Bumpus, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch, and Nicholas Lydon.
View insider buying and selling activity for Blueprint Medicines
.

Which major investors are buying Blueprint Medicines stock?

BPMC stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Macquarie Group Ltd., Bank of New York Mellon Corp, Alps Advisors Inc., Barclays PLC, Viking Global Investors LP, Swiss National Bank, and Dana Investment Advisors Inc..
View insider buying and selling activity for Blueprint Medicines
.

How do I buy shares of Blueprint Medicines?

Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Blueprint Medicines' stock price today?

One share of BPMC stock can currently be purchased for approximately $74.04.

How big of a company is Blueprint Medicines?

Blueprint Medicines has a market capitalization of $4.09 billion and generates $66.51 million in revenue each year. The biotechnology company earns $-347,690,000.00 in net income (profit) each year or ($7.27) on an earnings per share basis. Blueprint Medicines employs 217 workers across the globe.

What is Blueprint Medicines' official website?

The official website for Blueprint Medicines is www.blueprintmedicines.com.

How can I contact Blueprint Medicines?

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.